Last reviewed 2026-04-23 · How we verify

Moxifloxacin and Dexamethasone combined

Moxifloxacin and Dexamethasone combined is a Fluoroquinolone antibiotic + Corticosteroid combination Small molecule drug developed by Federal University of São Paulo. It is currently in Phase 3 development for Bacterial ocular infections with inflammatory component (phase 3 investigation), Post-operative ocular inflammation and infection prophylaxis. Also known as: vigadexa.

Moxifloxacin (a fluoroquinolone antibiotic) inhibits bacterial DNA gyrase and topoisomerase IV, while dexamethasone (a corticosteroid) suppresses inflammation and immune response.

Moxifloxacin (a fluoroquinolone antibiotic) inhibits bacterial DNA gyrase and topoisomerase IV, while dexamethasone (a corticosteroid) suppresses inflammation and immune response. Used for Bacterial ocular infections with inflammatory component (phase 3 investigation), Post-operative ocular inflammation and infection prophylaxis.

At a glance

Mechanism of action

This combination targets bacterial infection through moxifloxacin's inhibition of essential bacterial enzymes required for DNA replication and transcription, while dexamethasone reduces local and systemic inflammatory responses. The synergistic approach aims to control infection while minimizing inflammatory complications, particularly relevant in ocular or respiratory conditions where both infection and inflammation are pathogenic drivers.

Approved indications

• Bacterial ocular infections with inflammatory component (phase 3 investigation)
• Post-operative ocular inflammation and infection prophylaxis

Common side effects

• Ocular irritation or discomfort
• Transient vision disturbance
• Conjunctival hyperemia
• Systemic corticosteroid effects (with prolonged use)

Key clinical trials

• Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
• Safety/Efficacy of Antibiotic Steroid Combination in Treatment of Blepharitis and/or Keratitis and/or Conjunctivitis (PHASE3)
• Study of Efficacy and Safety of Vigadexa in Treating Inflammation and Infection Post-cataract Surgery (PHASE4)
• Efficacy/Safety of Antibiotic Steroid Combination in Prevention of Post Operative Inflammation in LASIK Surgery (NA)
• Efficacy/Safety of Antibiotic Steroid Combination in Prevention of Postoperative Inflammation in Cataract Surgery (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Moxifloxacin and Dexamethasone combined CI brief — competitive landscape report
• Moxifloxacin and Dexamethasone combined updates RSS · CI watch RSS
• Federal University of São Paulo portfolio CI

Frequently asked questions about Moxifloxacin and Dexamethasone combined

Related

• Drug class: All Fluoroquinolone antibiotic + Corticosteroid combination drugs
• Target: All drugs targeting Bacterial DNA gyrase, topoisomerase IV (moxifloxacin); Glucocorticoid receptor (dexamethasone)
• Manufacturer: Federal University of São Paulo — full pipeline
• Therapeutic area: All drugs in Infectious Disease / Ophthalmology
• Indication: Drugs for Bacterial ocular infections with inflammatory component (phase 3 investigation)
• Indication: Drugs for Post-operative ocular inflammation and infection prophylaxis
• Also known as: vigadexa
• Compare: Moxifloxacin and Dexamethasone combined vs similar drugs
• Pricing: Moxifloxacin and Dexamethasone combined cost, discount & access